Literature DB >> 30188559

In Vitro Blood-Brain Barrier Modeling adapted for Peripheral Blood Mononuclear Cell Transmigration from HIV-Positive Patients for Clinical Research on Therapeutic Drug Intervention.

Robert Oda1, Bruce Shiramizu2, Melissa Agsalda-Garcia2, Joanna Kettlewell2, Valerie Wojna3.   

Abstract

OBJECTIVE: HIV-associated cognitive impairment (HACI) continues to persist for HIV-seropositive individuals who are on antiretroviral therapy (ART). HACI develops in part when HIV-infected monocytes (MOs) transmigrate through the blood-brain barrier (BBB) and secrete pro-inflammatory cytokines and chemokines, which leads to neuronal damage. In vitro BBB models are important tools that can elucidate mechanisms of MO transmigration. Previously described in vitro BBB models relied on pathology specimens, resulting in potentially variable and inconsistent results. This project reports on a reliable and consistent alternative in vitro BBB model that has the potential to be used in clinical research intervention studies analyzing the effects of ART on the BBB and on MO transmigration.
METHODS: A bilayer BBB model was established with commercially available astrocytes and endothelial cells on a 3μm PET membrane insert to allow the contact of astrocytic foot processes with endothelial cells. Inserts were cultured in growth medium for 7 days before exposure to HIV- or HIV+ peripheral blood mononuclear cells (PBMCs). PBMCs were allowed to transmigrate across the BBB for 24 hours.
RESULTS: Confluency and integrity measurements by trans-endothelial electrical resistance (TEER) (136.7 ± 18.3Ω/cm2) and permeability (5.64 ± 2.20%) verified the integrity of the in vitro BBB model. Transmigrated MOs and non-MOs were collected and counted (6.0x104 MOs; 1.1x105 non-MOs). Markers indicative of glial fibrillary acidic protein (GFAP), von Willebrand factor (vWF), and p-glycoprotein (Pgp) were revealed in immunofluorescence staining (IF), indicating BBB phenotype and functionality.
CONCLUSION: Potential applications for this model include assessing the HIV DNA copy numbers of transmigrated cells (pre- and post-targeted ART) and understanding the role of oxidative stress related to HIV DNA and HACI.

Entities:  

Keywords:  Blood–brain barrier; Brain; Cognition; HIV; Neurocognition

Mesh:

Year:  2018        PMID: 30188559      PMCID: PMC6129984     

Source DB:  PubMed          Journal:  P R Health Sci J        ISSN: 0738-0658            Impact factor:   0.705


  19 in total

1.  Development of laboratory and animal model systems for HIV-1 encephalitis and its associated dementia.

Authors:  Y Persidsky; H E Gendelman
Journal:  J Leukoc Biol       Date:  1997-07       Impact factor: 4.962

2.  Chemokine-dependent mechanisms of leukocyte trafficking across a model of the blood-brain barrier.

Authors:  E A Eugenin; Joan W Berman
Journal:  Methods       Date:  2003-04       Impact factor: 3.608

3.  A fully human antibody to gp41 selectively eliminates HIV-infected cells that transmigrated across a model human blood brain barrier.

Authors:  Alicia McFarren; Lillie Lopez; Dionna W Williams; Mike Veenstra; Ruth A Bryan; Aliza Goldsmith; Alfred Morgenstern; Frank Bruchertseifer; Susan Zolla-Pazner; Miroslaw K Gorny; Eliseo A Eugenin; Joan W Berman; Ekaterina Dadachova
Journal:  AIDS       Date:  2016-02-20       Impact factor: 4.177

4.  Permeability of endothelial and astrocyte cocultures: in vitro blood-brain barrier models for drug delivery studies.

Authors:  Guanglei Li; Melissa J Simon; Limary M Cancel; Zhong-Dong Shi; Xinying Ji; John M Tarbell; Barclay Morrison; Bingmei M Fu
Journal:  Ann Biomed Eng       Date:  2010-04-02       Impact factor: 3.934

5.  JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals.

Authors:  Dionna W Williams; Kathryn Anastos; Susan Morgello; Joan W Berman
Journal:  J Leukoc Biol       Date:  2014-11-24       Impact factor: 4.962

6.  HIV-associated dementia, mitochondrial dysfunction, and oxidative stress.

Authors:  Victor Valcour; Bruce Shiramizu
Journal:  Mitochondrion       Date:  2004-07       Impact factor: 4.160

7.  Reversal of West Nile virus-induced blood-brain barrier disruption and tight junction proteins degradation by matrix metalloproteinases inhibitor.

Authors:  Saguna Verma; Mukesh Kumar; Ulziijargal Gurjav; Stephanie Lum; Vivek R Nerurkar
Journal:  Virology       Date:  2009-11-18       Impact factor: 3.616

8.  Purity, cell viability, expression of GFAP and bystin in astrocytes cultured by different procedures.

Authors:  Fang Du; Zhong Ming Qian; Li Zhu; Xiao Mei Wu; Christopher Qian; Robbie Chan; Ya Ke
Journal:  J Cell Biochem       Date:  2010-01-01       Impact factor: 4.429

9.  Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation.

Authors:  Anny-Claude Luissint; Cédric Artus; Fabienne Glacial; Kayathiri Ganeshamoorthy; Pierre-Olivier Couraud
Journal:  Fluids Barriers CNS       Date:  2012-11-09

10.  HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients.

Authors:  Victor G Valcour; Jintanat Ananworanich; Melissa Agsalda; Napapon Sailasuta; Thep Chalermchai; Alexandra Schuetz; Cecilia Shikuma; Chin-Yuan Liang; Supunee Jirajariyavej; Pasiri Sithinamsuwan; Somporn Tipsuk; David B Clifford; Robert Paul; James L K Fletcher; Mary A Marovich; Bonnie M Slike; Victor DeGruttola; Bruce Shiramizu
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

View more
  3 in total

1.  miR-98 reduces endothelial dysfunction by protecting blood-brain barrier (BBB) and improves neurological outcomes in mouse ischemia/reperfusion stroke model.

Authors:  David L Bernstein; Viviana Zuluaga-Ramirez; Sachin Gajghate; Nancy L Reichenbach; Boris Polyak; Yuri Persidsky; Slava Rom
Journal:  J Cereb Blood Flow Metab       Date:  2019-10-10       Impact factor: 6.200

2.  A dynamic perfusion based blood-brain barrier model for cytotoxicity testing and drug permeation.

Authors:  Basma Elbakary; Raj K S Badhan
Journal:  Sci Rep       Date:  2020-03-02       Impact factor: 4.379

3.  In vitro models of HIV-1 infection of the Central Nervous System.

Authors:  Celeste Faia; Karlie Plaisance-Bonstaff; Francesca Peruzzi
Journal:  Drug Discov Today Dis Models       Date:  2019-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.